

The University of Texas at El Paso - IBC Meeting
MEETING MINUTES | May 22, 2026 | Microsoft Teams

ATTENDANCE

Voting Members Present:	Das, Siddhartha (Chair) (Voting) Arriaga, Berenice (Voting) Dupre, Jo Anne (Voting) Moschak, Travis (Voting)	Baird, Anthony (Voting) Sharifan, Hamidreza (Voting) Llano, Manuel (Voting) Ibarra-Mejia, Gabriel (Voting)
Non-Voting Ex-Officio:	Gruszka, Dennis (Non-Voting)	Piramadathottathil Venu, Shonima (Non-Voting)
Minute Secretary:	Dean, Jacob	
Guests:	Lopez, Maryel	

1. Welcome and Opening Remarks

The meeting was called to order at 10:03 A.M by S. Das, Chair. Quorum was met with **8 of 13** voting members present at the start of the meeting.

2. Confidentiality of Panel Proceedings

The confidentiality statement was formally communicated to all members of the IBC.

3. Review of Previous Minutes

The committee read and reviewed the minutes from the following meetings:

- A motion was made and seconded to **approve** the minutes from **March 27, 2026; 8 in favor, 0 opposed, 0 abstentions.**
- A motion was made and seconded to **approve** the minutes from **April 24, 2026; 8 in favor, 0 opposed, 0 abstentions.**

4. Discussion and Appropriate Actions Regarding Protocols to be Reviewed by the Full Board

4.1. Immune and chemotherapeutic approaches against Leishmaniasis

Reference Number: 26-02-170 | **Principal Investigator:** Maldonado, Rosa | **Presenter:** Moschak, Travis

Discussion: A protocol involving Section III-D-1 and Section III-F-6, and issues such as rDNA, biological agents, safety and handling, and risk mitigation were discussed. **Decision:** A motion was made and seconded to return the protocol for modifications; **8 in favor, 0 opposed, 0 abstentions.**

4.2. Bacterial-host interactions in the tumor microenvironment

Reference Number: 25-07-108 | **Principal Investigator:** Galeano Nino, Jorge | **Presenter:** Vines, Charlotte

Discussion: A protocol amendment involving Section III-D-1 and Section III-F-6, and issues such as rDNA, biological agents, safety and handling, and risk mitigation were discussed. **Decision:** A motion was made to **approve the amendment with conditions;** seconded; **8 in favor, 0 opposed, 0 abstentions.**

4.3. Use of Second-Generation Lentiviral Packaging System for Gene Delivery in Pancreatic Cancer Cells

Reference Number: 26-01-152 | **Principal Investigator:** Lu, Weiqin | **Presenter:** Llano, Manuel

Discussion: A protocol amendment involving Section III-D-1, and issues such as rDNA, biological agents, safety and handling, and risk mitigation were discussed. **Decision:** A motion was made to **approve the amendment with conditions**; seconded; **8 in favor, 0 opposed, 0 abstentions**.

5. Discussion and Appropriate Action regarding the following matters

- 5.1. PAVE Program Report and Committee Education:** Maryel Lopez presented the PAVE (Post-Approval Verification and Education) program to the committee, explaining its routine and for-cause evaluation processes, report structure, and its role as a support unit for PIs and committees.
- 5.2. Committee Process Improvements and Charter Review:** The committee discussed improving committee review processes by establishing deadlines, clarifying reviewer roles, and revising the Charter to expedite protocol approvals and ensure all members have access to protocols.
- 5.3. Announcement of Committee Member Departure:** Dennis Gruszka announced their departure from the IBC Office, with the committee expressing gratitude for his contributions and support during his tenure.

6. Adjournment

The meeting was adjourned at 11:24 A.M.

7. A LIST OF THE PROTOCOLS AND AMENDMENTS APPROVED SINCE THE LAST MEETING:

- 7.1. Immune and Chemotherapeutic Approaches against Chagas Disease**
Reference Number: 25-10-125 | **Submission Type:** New | **Action:** Approved
- 7.2. Determination of Mitochondria Membrane Potential using JC-1 and Mitotracker Fluorescent Probes**
Reference Number: 26-03-173 | **Submission Type:** New | **Action:** Approved
- 7.3. Synthesis of alpha-galactosyl glycolipid nanoparticles and their effects on macrophages**
Reference Number: 25-07-109 | **Submission Type:** Amendment | **Action:** Approved
- 7.4. Engineering nanoparticles for biomedical applications**
Reference Number: 25-10-128 | **Submission Type:** Amendment | **Action:** Approved